Table 80.
Locally acquired human WNND cases (confirmed and probable) and notification rates per 100,000 population in the EU MSs and non‐MS countries, by country and year, 2017–2021
| Country | 2021 | 2020 | 2019 | 2018 | 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| National coverage (a) | Data format (a) | Confirmed cases | Total cases* and rates | Total cases* and rates | Total cases* and rates | Total cases* and rates | Total cases* and rates | ||||||
| Cases | Rate | Cases | Rate | Cases | Rate | Cases | Rate | Cases | Rate | ||||
| Austria | Y | C | 1 | 1 | 0.01 | 0 | 0 | 1 | 0.01 | 4 | 0.05 | 2 | 0.02 |
| Belgium | Y | C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bulgaria | Y | C | 0 | 0 | 0 | 1 | 0.01 | 4 | 0.06 | 13 | 0.18 | 1 | 0.01 |
| Croatia | Y | C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 47 | 1.1 | 5 | 0.12 |
| Cyprus | Y | C | 0 | 0 | 0 | 0 | 0 | 20 | 2.3 | 1 | 0.12 | 0 | 0 |
| Czechia | Y | C | 0 | 0 | 0 | 0 | 0 | 1 | 0.01 | 3 | 0.03 | 0 | 0 |
| Denmark (b) | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Estonia | Y | C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Finland | Y | C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| France | Y | C | 0 | 0 | 0 | 0 | 0 | 1 | < 0.01 | 7 | 0.01 | 0 | 0 |
| Germany | Y | C | 2 | 2 | < 0.01 | 7 | 0.01 | 3 | < 0.01 | 0 | 0 | – | – |
| Greece (c) | Y | C | 22 | 38 | 0.36 | 116 | 1.1 | 140 | 1.3 | 241 | 2.2 | 28 | 0.26 |
| Hungary | Y | C | 6 | 7 | 0.07 | 1 | 0.01 | 23 | 0.24 | 152 | 1.6 | 17 | 0.17 |
| Ireland | Y | C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Italy | Y | C | 35 | 35 | 0.06 | 46 | 0.08 | 24 | 0.04 | 243 | 0.40 | 26 | 0.04 |
| Latvia | Y | C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lithuania | Y | C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Luxembourg | Y | C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malta | Y | C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Netherlands | Y | C | 0 | 0 | 0 | 6 | 0.03 | 0 | 0 | 0 | 0 | 0 | 0 |
| Poland | Y | C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Portugal | Y | C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Romania | Y | C | 6 | 7 | 0.04 | 6 | 0.03 | 65 | 0.33 | 277 | 1.4 | 66 | 0.34 |
| Slovakia | Y | C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Slovenia | Y | C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0.19 | 0 | 0 |
| Spain | Y | C | 6 | 6 | 0.01 | 72 | 0.15 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sweden | Y | C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EU Total 27 | – | – | 78 | 96 | 0.02 | 255 | 0.06 | 282 | 0.06 | 992 | 0.23 | 145 | 0.04 |
| United Kingdom | – | – | – | – | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 |
| EU Total (d) | – | – | 78 | 96 | 0.02 | 255 | 0.06 | 282 | 0.06 | 992 | 0.20 | 145 | 0.03 |
| Iceland | Y | C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Norway | Y | C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Liechtenstein | Y | C | 0 | 0 | 0 | – | – | – | – | – | – | – | – |
| Switzerland (e) | Y | C | – | – | – | ||||||||
WNND: West Nile Neuro‐invasive Disease.
–: Data not reported.
: Y: yes; N: no; A: aggregated data; C: case‐based data.
: No surveillance system.
: Only locally acquired cases diagnosed in the country of exposure are included in the table.
: Cases reported by the United Kingdom for the period 2017–2020 were also considered for this estimation (EU‐28). When the United Kingdom data were collected for the period 2017–2020, the United Kingdom was an EU MS, but it became a third country on 1 February 2020.
: Switzerland provided data directly to EFSA. The human data for Switzerland include data from Liechtenstein for the years 2017–2020.